Upper Tract Urothelial Cancer (UTUC) is a rare malignancy occurring in the lining of the upper urinary tract, involving the renal pelvis and ureters. Accurate documentation, coding, and billing are essential for ensuring proper reimbursement, compliance, and optimal patient management.

Patients with either newly diagnosed or recurrent upper tract urothelial tumors are first evaluated for endoscopic manageability. Based on that assessment, treatment options are as follows:

• If the tumor is endoscopically manageable
  • Visible disease is resected or ablated through endoscopic procedures.
  • Post-resection, chemoablation is used:
    • JELMYTO is administered once weekly for six weeks.
    • This approach is designed to treat any residual disease that may remain after visible tumor resection.
• If the tumor is unresectable via endoscopic means
  • Chemoablation is initiated directly without resection.
  • The goal in this case is to spare the kidney by treating the unresectable disease in a non-surgical manner using JELMYTO.
• Open treatment options
  • Radical nephrectomy
  • Partial nephrectomy
  • Nephroureterectomy
  • Partial or total ureterectomy